Formulation Development for Transdermal Delivery of Raloxifene, a Chemoprophylactic Agent against Breast Cancer

Raloxifene (RLX) is a second-generation selective estrogen receptor modulator approved for the prevention of invasive breast cancer in women. Oral therapy of RLX requires daily intake and is associated with side effects that may lead to low adherence. We developed a weekly transdermal delivery syste...

Descripción completa

Detalles Bibliográficos
Autores principales: Vora, Deepal, Dandekar, Amruta, Bhattaccharjee, Sonalika, Singh, Onkar N., Agrahari, Vivek, Peet, M. Melissa, Doncel, Gustavo F., Banga, Ajay K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953220/
https://www.ncbi.nlm.nih.gov/pubmed/35336054
http://dx.doi.org/10.3390/pharmaceutics14030680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953220/
https://www.ncbi.nlm.nih.gov/pubmed/35336054
http://dx.doi.org/10.3390/pharmaceutics14030680

Ejemplares similares